Product Description
Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Procarbazine)
Mechanisms of Action: Protein Synthesis Inhibitor,DNA Synthesis Inhibitor,RNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Canada | Chile | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Japan | Lithuania | Malta | New Zealand | Pakistan | Peru | Portugal | Romania | Russia | Slovenia | Spain | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: CHU de DIJON
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Spain
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Glioma|Hodgkin Lymphoma|Primary Central Nervous System Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-005027-16 | P3 |
Active, not recruiting |
Glioma |
2030-09-14 |
|
| PRIMA-CNS | P3 |
Recruiting |
Primary Central Nervous System Lymphoma |
2029-08-31 |
|
| HD21 (advanced stage) | P3 |
Active, not recruiting |
Hodgkin Lymphoma |
2025-10-18 |
|
| FIORELLA Trial | P2 |
Active, not recruiting |
Primary Central Nervous System Lymphoma |
2025-05-01 |